Imvelaphi
Unyango olusekwe kwi-Incretin kudala lusaziwa ukuba luphucule zombiniukulawula iswekile yegazikwayeukunciphisa ubunzima bomzimba. Amachiza esintu e-incretin ajolise ikakhulu kwiI-GLP-1 i-receptor, ngelixaTirzepatideimele isizukulwana esitsha “twincretin” ii-arhente — ziqhubela phambilizombini i-GIP (i-insulinotropic polypeptide exhomekeke kwiglucose)kwayeI-GLP-1abamkeli.
Esi senzo sintlu-mbini sibonakaliswe sokuphucula izibonelelo ze-metabolic kunye nokukhuthaza ukwehla okukhulu kobunzima xa kuthelekiswa ne-GLP-1 agonists kuphela.
Uyilo lweSifundo se-SURMOUNT-1
UMZAMO-1yaba ai-randomized, i-double-blind, isigaba sesi-3 solingo lwezonyangoiqhutywe kwiindawo ezili-119 kumazwe alithoba.
Abathathi-nxaxheba baquka abantu abadala ababe:
- Utyebile(BMI ≥ 30), okanye
- Ukutyeba ngokugqithisileyo(BMI ≥ 27) ubuncinane obunye ubunzima obunxulumene nobunzima (umzekelo, uxinzelelo lwegazi, i-dyslipidemia, i-apnea yokulala, okanye isifo senhliziyo).
Abantu abanesifo seswekile, ukusetyenziswa kweziyobisi zamva nje, okanye utyando lwangaphambili lwe-bariatric ababandakanywanga.
Abathathi-nxaxheba babelwa ngokungenamkhethe ukuba bafumane inaliti kanye ngeveki:
- Tirzepatide 5 mg, 10 mg, 15 mg, okanye
- Indawo
Bonke abathathi-nxaxheba bafumene isikhokelo sendlela yokuphila:
- A i-caloric deficit ye-500 kcal / ngosuku
- KungconoImizuzu eyi-150 yokuzivocavoca umzimba ngeveki
Unyango lwathabathaIiveki ezingama-72, kuquka aIsigaba sokunyuka kwedosi yeeveki ezingama-20kulandelwa lixesha lokugcinwa kweeveki ezingama-52.
Isishwankathelo seziphumo
Iyonke yeNgama-2,359 abathathi-nxaxhebababhaliswa.
Umndilili weminyaka wawu44.9 iminyaka, I-67.5% ibingabasetyhini, ngengqiqoubunzima bomzimba 104.8 kgkwayeI-BMI ye-38.0.
Ukunciphisa ubunzima bomzimba kwiVeki yama-72
| Iqela lethamo | % Ukutshintsha kobunzima | Ukutshintsha kobunzima obuqhelekileyo (kg) | Ilahleko eyongezelelweyo vs Placebo |
|---|---|---|---|
| 5 mg | -15.0% | -16.1 kg | -13.5% |
| 10 mg | -19.5% | -22.2 kg | -18.9% |
| 15 mg | -20.9% | -23.6 kg | -20.1% |
| Indawo | -3.1% | -2.4 kg | - |
I-Tirzepatide iphumelele i-15-21% ithetha ukunciphisa umzimba, ebonisa iziphumo ezicacileyo ezixhomekeke kumthamo.
Ipesenti yabathathi-nxaxheba abaPhumelela ukuLahla kobunzima ekujoliswe kuko
| Ukuhla ukusinda (%) | 5 mg | 10 mg | 15 mg | Indawo |
|---|---|---|---|---|
| ≥5% | 85.1% | 88.9% | 90.9% | 34.5% |
| ≥10% | 68.5% | 78.1% | 83.5% | 18.8% |
| ≥15% | 48.0% | 66.6% | 70.6% | 8.8% |
| ≥20% | 30.0% | 50.1% | 56.7% | 3.1% |
| ≥25% | 15.3% | 32.3% | 36.2% | 1.5% |
Ngaphezu kwesiqingathayabathathi-nxaxheba abafumanayo≥10 mgI-Tirzepatide ifunyenwe≥20% ukwehla kobunzima, ukusondela kwisiphumo esibonwa ngotyando lwe-bariatric.
Izibonelelo zeMetabolic kunye neCardiovascular
Xa kuthelekiswa ne-placebo, iTirzepatide iphuculwe kakhulu:
- Umjikelo wesinqe
- Uxinzelelo lwegazi lweSystolic
- Iprofayile ye-lipid
- Ukuzila ukutya amanqanaba e-insulin
Phakathi kwabathathi-nxaxheba abaneprediabetes, I-95.3% ibuyele kumanqanaba aqhelekileyo e-glucose, kuthelekiswa ne61.9%kwiqela le-placebo - ebonisa i-Tirzepatide ayincedi kuphela ekunciphiseni ubunzima kodwa iphucula i-glucose metabolism.
Ukhuseleko kunye nokunyamezeleka
Ezona ziphumo bezingalindelekanga zixhaphake kakhuluesiswini, kuqukaisicaphucaphu, urhudo, kunye nokuqhinwa, ubukhulu becala buthambile kwaye budlula.
Izinga lokuyeka ngenxa yeziganeko ezimbi lalimalunga4–7%.
Ukufa okumbalwa kwenzeka ngexesha lovavanyo, olunxulunyaniswa neI-COVID-19, kwaye bezinganxulumananga ngokuthe ngqo neyeza lophononongo.
Akukho mahluko abalulekileyo abonwe kwiingxaki ezinxulumene ne-gallbladder.
Ingxoxo
Ukuguqulwa kwendlela yokuphila kuphela (ukutya kunye nokuzilolonga) kuvelisa kuphela~ 3% ukulahleka kwesisindo esiphakathi, njengoko kubonwa kwiqela le-placebo.
Ngokwahlukileyo, iTirzepatide yenziwe yasebenzaI-15-21% yokunciphisa umzimba wonke, emele aAmaxesha ama-5-7 isiphumo esikhulu.
Xa kuthelekiswa ne:
- Amachiza okunciphisa ubunzima bomlomo:ngokuqhelekileyo ukufikelela kwi-5-10% ilahleko
- Utyando lweBariatric:ifezekisa > 20% ilahleko
I-Tirzepatide ivala umsantsa phakathi kwe-pharmacologic kunye nongenelelo lotyando-umnikeloenamandla, non-invasive ukunciphisa ubunzima.
Okubalulekileyo, ukuxhalabisa malunga nokunyuka kwe-glucose metabolism akuzange kubonwe. Ngokuchasene noko, i-Tirzepatide iphucule ukuvakalelwa kwe-insulin kunye nokubuyisela umva i-prediabetes kuninzi lwabathathi-nxaxheba.
Nangona kunjalo, olu lingo luthelekisa iTirzepatide kunye ne-placebo - hayi ngokuthe ngqoSemaglutide.
Ukuthelekiswa kwentloko-entloko kuyadingeka ukugqiba ukuba yiyiphi i-arhente evelisa ukulahleka kwesisindo esikhulu.
Ukuqukumbela
Kubantu abadala abanokutyeba kakhulu okanye ukutyeba kakhulu kunye ne-comorbidities ehambelanayo, ukongezakanye ngeveki iTirzepatidekwinkqubo yokuphila ehleliweyo (ukutya + umthambo) kunokukhokelela ku:
- I-15-21% i-avareji yokunciphisa umzimba
- Uphuculo olubalulekileyo lwemetabolism
- Ukunyamezela okuphezulu kunye nokhuseleko
I-Tirzepatide ke ngoko imele unyango olusebenzayo kunye noluqinisekisiweyo lweklinikhi oluzinzileyo, ulawulo lobunzima obuphantsi kolawulo.
Ixesha lokuposa: Oct-16-2025